$2.38
-0.03 (-1.24%)
Open$2.41
Previous Close$2.41
Day High$2.41
Day Low$2.36
52W High$3.24
52W Low$1.30
Volume—
Avg Volume326.6K
Market Cap227.87M
P/E Ratio6.54
EPS$0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,852.1% upside
Current
$2.38
$2.38
Target
$46.46
$46.46
$33.82
$46.46 avg
$60.35
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 36.56M | 14.58M | 13.34M |
| Net Income | 36.07M | 2.88M | 3.22M |
| Profit Margin | -56.1% | 19.8% | 24.2% |
| EBITDA | 32.46M | 4.55M | 4.43M |
| Free Cash Flow | — | 4.06M | 3.77M |
| Rev Growth | — | -8.4% | -7.1% |
| Debt/Equity | — | 0.65 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |